转移灶导向立体定向放疗联合全身治疗继续用于寡进展转移性乳腺癌患者
这项前瞻性-回顾性、单中心队列研究纳入129例接受全部颅外寡进展病灶(≤5个)SBRT且不改变全身治疗的转移性乳腺癌患者,中位放疗后无进展生存期为11.3个月(95%CI 9.1-13.5),中位至下次全身治疗时间为13.6个月(95%CI 11.5-15.2),仅19例(15%)在SBRT治疗的寡进展部位出现后续进展。
要点
- 129例患者中99例(77%)为HR+/HER2-,116例(90%)寡进展病灶≤2个,118例(91%)为非内脏寡进展。
- 中位放疗后无进展生存期为11.3个月(95%CI 9.1-13.5),中位至下次全身治疗时间为13.6个月(95%CI 11.5-15.2)。
- 仅19例(15%)患者在SBRT治疗的寡进展部位出现后续进展。
核心结论
- 寡进展转移性乳腺癌患者,尤其是HR+/HER2-且非内脏寡进展、既往全身治疗无进展生存期较长的患者,可从寡进展灶导向SBRT并维持原全身治疗中获益,作者提示可在临床实践中更广泛实施。
研究设计与样本
- 前瞻性-回顾性、单中心队列研究,连续纳入2011年1月至2023年6月接受全部颅外寡进展部位(≤5个)SBRT且不改变全身治疗的患者,依据多学科肿瘤委员会指征。
- 样本量需130例以估算中位放疗后无进展生存期为8个月、95%CI从5.4个月(临床显著)至10.6个月。
主要发现
- 共纳入129例患者:99例(77%)为激素受体阳性/HER2阴性(HR+/HER2-)疾病,116例(90%)寡进展病灶≤2个,118例(91%)为非内脏寡进展(骨或淋巴结)。
- 患者既往全身治疗的中位无进展生存期(寡进展前PFS)为11.3个月(95%CI 8.7-13.0)。
- 中位放疗后无进展生存期为11.3个月(95%CI 9.1-13.5),中位至下次全身治疗时间为13.6个月(95%CI 11.5-15.2)。
- 仅19例(15%)患者在SBRT治疗的寡进展部位出现后续疾病进展。
临床怎么用
- 作者认为,对于寡进展转移性乳腺癌患者,尤其是HR+/HER2-且非内脏寡进展、既往全身治疗无进展生存期较长的患者,可从寡进展灶导向SBRT并维持原全身治疗中获益,提示可在临床实践中更广泛实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: About 15-20 % of patients with metastatic breast cancer (mBC) can experience oligoprogressive disease (OPD) in ≤ 5 sites of disease. Patients with OPD may benefit from metastasis-directed stereotactic radiotherapy (SBRT) to all sites of cancer progression while maintaining the same systemic treatment, aiming to prolong the time to next systemic treatment (NEST). This study aims to assess the outcomes provided by this multimodal strategy. METHODS: Prospective-retrospective, single-center, cohort study including consecutive patients who received SBRT to all extracranial OPD sites (≤ 5), from January 2011 to June 2023, without changing systemic therapy, according to the multidisciplinary tumor board's indication. The primary endpoint was post-radiotherapy progression-free survival (pRT-PFS). A sample size of 130 patients was needed to estimate a median pRT-PFS of 8 months with a 95 % confidence interval (95 %CI) ranging from 5.4 (considered clinically significant) to 10.6 months. RESULTS: 129 patients were included: 99 (77 %) had hormone receptor-positive/HER2-negative (HR+/HER2-) disease, 116 (90 %) had ≤ 2 oligoprogressive lesions, 118 (91 %) presented with non-visceral OPD involving bones or lymph nodes. Patients experienced OPD after a median PFS on systemic therapy (pre-OPD PFS) of 11.3 months (95 % CI, 8.7-13.0). Median pRT-PFS was 11.3 months (95 % CI, 9.1-13.5) and median NEST was 13.6 months (95 % CI, 11.5-15.2). Only 19 (15 %) patients experienced a subsequent PD in the OPD sites treated with SBRT. CONCLUSION: Patients with oligoprogressive mBC, especially with HR+/HER2- disease and non-visceral OPD after a durable pre-OPD PFS, benefit from OPD-directed SBRT while maintaining the same systemic treatment, suggesting its broader implementation in clinical practice.
引用
- Milano M, Valenza C, Ferrari A, et al. Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer. Eur J Cancer. 2024. PMID: 39662096. doi:10.1016/j.ejca.2024.115164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。